CYCLO THERAPEUTICS INC (CYTH) Stock News

Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals

Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025

Mentions: RFL

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Mentions: PTN CAPS BSGM POAI ...

12 Health Care Stocks Moving In Thursday's After-Market Session

Mentions: IBO INTS EYEN PSTV ...

Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results

Mentions: RFL

CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH

Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)

Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium™ 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LTRPA, LTRPB, CYTH, SKGR on Behalf of Shareholders

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

Mentions: SKGR

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates USAP, FLIC, ARCH, CYTH on Behalf of Shareholders

Mentions: USAP FLIC ARCH

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ZUO, ARCH, CYTH on Behalf of Shareholders

Mentions: ZUO ARCH

Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results

Upon completion of our proposed merger with Cyclo Therapeutics the Company intends to focus its efforts on Cyclo’s lead clinical program Trappsol® Cyclo™

Mentions: RFL

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENLC, ALVR, CYTH on Behalf of Shareholders

Mentions: ENLC ALVR

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates USAP, CYTH, ARCH on Behalf of Shareholders

Mentions: USAP ARCH

Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

Our proposed merger with Cyclo Therapeutics advances our strategy to invest in, develop and commercialize clinical stage assets which address areas of high unmet medical need

Mentions: RFL

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer

Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience

Mentions: PCRX

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CrossFirst Bankshares, Inc. (Nasdaq - CFB), Arch Resources, Inc. (NYSE - ARCH), Cyclo Therapeutics, Inc. (Nasdaq - CYTH), Vector Group Ltd. (NYSE - VGR)

Mentions: CFB BUSE ARCH CEIX ...

Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VGR, ARCH, CYTH on Behalf of Shareholders

Mentions: VGR ARCH

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CrossFirst Bankshares, Inc. (Nasdaq - CFB), Arch Resources, Inc. (NYSE - ARCH), Cyclo Therapeutics, Inc. (Nasdaq - CYTH), Vector Group Ltd. (NYSE - VGR)

Mentions: CFB ARCH VGR BUSE ...

CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VGR, SDIG, ARCH, CYTH on Behalf of Shareholders

Mentions: VGR SDIG ARCH

Shareholder Alert: Ademi LLP investigates whether Cyclo Therapeutics, Inc. has obtained a Fair Price for its Public Shareholders

/PRNewswire/ -- Ademi LLP is investigating Cyclo Therapeutics (Nasdaq: CYTH) for possible breaches of fiduciary duty and other violations of law in its...